Whilst mutations in RAS genes are relatively low in PCa [93], ranging from 2.25 to 9.68% of cases across various datasets on cBioPortal (Figure 11), it is thought that RAS de-regulation contributes towards metastasis and, in combination with PTEN loss, can accelerate cancer progression [94]. The gene discussed is PTEN; the disease is posterior cortical atrophy.